Companies › Aurinia Pharmaceuticals
2 active drug programs in 4 registered trials: 3 Phase 4, 1 Phase 1; Immunology, Neurology; next expected readout Mar 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| voclosporin Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor | PPP3CA | Phase 4 | Lupus Nephritis | Mar 2029 |
| Aritinercept BAFF receptor (BAFF-R) agonist | TNFRSF13B | Phase 1 | Myasthenia Gravis, Generalized | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07225387 | voclosporin | Phase 4 | Lupus Nephritis | Immunology | Jan 2027 |
| NCT07760480 | voclosporin | Phase 4 | Lupus Nephritis | Immunology | Apr 2028 |
| NCT07611214 | voclosporin | Phase 4 | Lupus Nephritis | Immunology | Mar 2029 |
| NCT07596901 | Aritinercept | Phase 1 | Myasthenia Gravis, Generalized | Neurology | Mar 2029 |
Cash of $46m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
TG Therapeutics Vor Biopharma Hope Biosciences Research Foundation Kyverna Therapeutics Q32 Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.